Revolution Medicines (RVMD) Non-Current Assets (2019 - 2026)

Revolution Medicines has reported Non-Current Assets for 8 years, with the latest figure at $285.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 23.86% year-over-year to $285.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 31.83% YoY), and the FY2025 full-year result was $279.5 million, up 21.16% from the prior year.
• Non-Current Assets for Q1 2026 stood at $285.8 million, up from $279.5 million in the prior quarter.
• The five-year high for Non-Current Assets was $285.8 million in Q1 2026, with the low at $148.4 million in Q1 2022.
• Average Non-Current Assets over 5 years is $196.8 million, with a median of $182.4 million recorded in 2023.
• Year-over-year, Non-Current Assets advanced 1.24% in 2023 and surged 49.26% in 2025.
• Tracing RVMD's Non-Current Assets over 5 years: stood at $151.7 million in 2022, then rose by 20.22% to $182.4 million in 2023, then advanced by 26.45% to $230.7 million in 2024, then grew by 21.16% to $279.5 million in 2025, then gained by 2.27% to $285.8 million in 2026.
• The last three Non-Current Assets figures came in at $285.8 million (Q1 2026), $279.5 million (Q4 2025), and $274.4 million (Q3 2025), per Business Quant data.

Peer Comparison